PlexSet reagents are compatible with a wide range of sample types, including total purified RNA from FFPE and fresh/frozen samples or cell lysates which can be processed with a simple "lyse-and-go" protocol for whole cells. This new technology is suitable for a variety of project types and can be used in any biological system where gene expression analysis is the marker of interest. Key applications include cell line screening, biomarker validation, drug screening and CRISPR studies.
"PlexSet technology eliminates the need for upfront probe validation and dramatically reduces the hands-on time required to process samples," said
"PlexSet technology has the potential to provide an effective workflow to save us time and resources - which allows
for direct detection from cell lysates and elimination of steps such as RNA purification, cDNA conversions, or upfront probe validations," said Dr.
Location: (SW5) Genome Engineering using
ABRF 3D Biology™ Luncheon Seminar
Location: Platinum Presentations
NanoString ABRF PlexSet Poster Presentation
These new technologies demonstrate
For more information, please visit http://www.nanostring.com/PlexSet
For Research Use Only. Not for use in diagnostic procedures.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for
use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential for researchers to increase efficiency and reduce costs and the use of resources through the use of PlexSet assays. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
Doug FarrellVice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768
News Provided by Acquire Media